Baliopharm GmbH, a subsidiary of Baliopharm AG, of Basel, Switzerland, joined the NEU2 Consortium with a project addressing the recombinant manufacturing of an Fc-free bispecific CD20-CD95 antibody construct (Novotarg) with selectivity for activated B cells and efficacy studies in disease models relevant to multiple sclerosis therapy. The two-year project was funded by the German Federal Ministry of Education and Research. Bayer AG, of Leverkusen, Germany, signed an agreement to acquire the

At the Annual Meeting of the American Association for Cancer Research in April, a Novartis scientist involved in the clinical trials for autologous engineered T cells for the treatment of leukemia noted that "our product can be improved in real time," and that the manufacturing process is constantly adjusted in response to patient data

Kevin Harrington, professor in biological cancer therapies at London's Institute of Cancer Research

VBL Therapeutics Inc., of Tel Aviv, said Phase I data for VB-111 were published in the journal Clinical Cancer Research

The nivolumab findings reinforced promising data about the compound presented at ASCO 2012 and earlier this year at the American Association for Cancer Research annual meeting. (See BioWorld Today, June 4, 2012, and April 15, 2013.) The Street took notice, too, sending BMS shares (NYSE:BMY) up 5 percent Wednesday even before ASCO abstracts were released

Cancer Research UK licensed data from its Phase II study of rucaparib (AG014699) in breast and ovarian cancer patients with known BRCA 1 or 2 mutations to Clovis Oncology Inc., of Boulder, Colo., in return for undisclosed licensing fees...The compound was initially developed by Cancer Research UK-funded laboratories and then in collaboration with Agouron Pharmaceuticals Inc., which was acquired by Warner-Lambert Co

Cancer Research UK licensed data from its Phase II study of rucaparib (AG014699) in breast and ovarian cancer patients with known BRCA 1 or 2 mutations to Clovis Oncology Inc., of Boulder, Colo., in return for undisclosed licensing fees...The compound was initially developed by Cancer Research UK-funded laboratories and then in collaboration with Agouron Pharmaceuticals Inc., which was acquired by Warner-Lambert Co

Company (Location) Product Description Indication Status Date Activartis Biotech GmbH (Vienna, Austria) AVO113 Consists of dendritic cells loaded with antigens derived from each patient's tumor Glioblastoma The first interim analysis in a Phase III trial indicated there will be an overall survival benefit in treated patients 4/10/13 Aprea AB (Stockholm, Sweden) APR-246 Designed to reactivate mutant p53 Ovarian cancer Results showed that APR-246 acts synergistically with platinum compounds and

Symphogen presented preclinical data on Sym013 at the American Association for Cancer Research meeting in Washington last month, showing that the pan-HER mixture suppresses tumor growth in multiple xenograft models

Symphogen presented preclinical data on Sym013 at the American Association for Cancer Research meeting in Washington last month, showing that the pan-HER mixture suppresses tumor growth in multiple xenograft models

But it would be well short of the $6 billion the NIH spends on cancer research each year or the $3 billion spent on HIV/AIDS research, Ronald Petersen, director of the Mayo Alzheimer's Disease Research Center and chairman of the Advisory Council on Research, Care and Services for the National Alzheimer's Project Act (NAPA), told the committee

A presentation of Phase I data at the recent American Association of Cancer Research (AACR) meeting in Washington showed that the drug was safe and well tolerated at the maximum-tolerated dose of 60 mg/m2, with signs of antitumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four cycles

A presentation of Phase I data at the recent American Association of Cancer Research (AACR) meeting in Washington showed that the drug was safe and well tolerated at the maximum-tolerated dose of 60 mg/m2, with signs of antitumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four cycles

MD Anderson also will be entitled to royalties from the commercial sales of products developed 12/10/12 GlaxoSmithKline plc (London) Fred Hutchinson Cancer Research Center ND Partnership to develop therapeutics to treat an inherited form of muscular dystrophy The goal of the agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the

the renewal extends the agreement until Dec. 31, 2013 2/1/13 MARCH Cancer Research Technology (London) AstraZeneca plc (London) ND Extended their multiproject cancer metabolism alliance for another two years The alliance aims to develop a drug pipeline targeting cancer metabolism

And More Check out BioWorld Today's comprehensive coverage of the American Association for Cancer Research Annual Meeting held in Washington D.C. The Chinese Center for Disease Control and Prevention has reported 16 confirmed human cases of avian influenza H7N9

WASHINGTON – At the annual meeting of the American Association for Cancer Research (AACR) last week, researchers were touting the potential of immunotherapies at the same time as they were trying to figure out how to meet their unique regulatory and developmental challenges...Despite those challenges, Shen was enthusiastic about the approach, telling the audience that "personalized and targeted cell therapy is one of the most exciting frontiers in cancer research" and the CAR technology is "poised